Medtronic made a necessary purchase of Biophan's intellectual property for its newly-introduced MRI-safe pacemaker product line. They got off pretty cheap: $11 million, and avoided later legal challenges that were sure to arise if they had not made the purchase. The next question is, since Biophan was best-known for their work in this space, will they have enough intellectual property left to survive?
-Wes
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.